Abstract: The present invention is directed to a setting system for use in the making of gelatin desserts comprising gelatin and an anionic hydrocolloid gum wherein the weight ratio of gelatin to anionic hydrocolloid gum is approximately 250-375:1. Through the use of such a setting system, lower gelatin use of up to 10% or more can be realized while achieving an increase in gel strength of up to about 20%.

Abstract: Disclosed are expression vectors useful as vectors in recombinant methods to facilitate expression of exogenous genes in E. coli. Specifically, the disclosed expression vector has the following elements in operable linkage: the PL6m promoter, the TAT32 ribosome binding site and a gene encoding a heterologous polypeptide, Also disclosed are E. coli host cells transformed with this expression vector.

Abstract: The present invention is based upon the discovery that proteins made from genes that include the CD4 sequence in its cDNA can make additional polypeptides as a result of internal translation initiation. This invention is thus directed to DNA sequences which eliminate internal initiation expression in sCD4.

Abstract: The present invention relates to the use of taxol dependent cells, e.g. Tax 2-4 CHO cell line, as the basis of a screen for taxol or taxol-like compounds.

Abstract: The present invention provides an inactivated encephalomyocarditis virus (EMCV) vaccine produced from swine isolates which protects swine from diseases caused by EMCV. The vaccine is produced from swine isolates and protects against respiratory problems, myocardial and pulmonary inflammation and necrosis, and confers protection against reproductive disorders resulting from some strains of the virus.

Abstract: Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain that are useful for treating phospholipase A2 mediated conditions, diabetes, and obesity.

Abstract: Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain.

Abstract: Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain that are useful for treating phospholipase A2 mediated conditions, diabetes, and obesity.

Abstract: The present invention provides a method for treating or preventing certain metabolic disorders comprising the systemic administration of 3-guanidinopropionic acid.

Abstract: The present invention provides a method for treating or preventing certain metabolic disorders comprising the systemic administration of 3-guanidinopropionic acid.

Abstract: This invention discloses human tissue plasminogen activator (TPA) analogs. The analogs are TPA-like molecules that have had the native domain regions either rearranged, delected, added or a combination thereof. The analogs are the product of the expression of recombinant DNA also described herein. Additonally, the present invention described replication and expression plasmids containing the TPA-coding DNA sequences described above and suitable host microorganisms that are capable of expressing the TPA analogs after becoming transformed with an appropriate plasmid.

Abstract: This invention is a compound of formula 1 and pharmaceutically acceptable salts thereof; ##STR1## wherein R.sub.1 is fluorine, chlorine or bromine; wherein R.sub.2 is hydrogen or (C.sub.1 -C.sub.3) alkyl; wherein n is one or 2; wherein R.sub.3 is phenyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl; wherein phenyl is optionally substituted with one substituent selected from the group consisting of halogen, trifluoromethyl or sulfonamide. These compounds are useful as hypoglycemic agents.

Abstract: This invention provides novel cyclic hydrocarbons of the formula: ##STR1## wherein R is selected from the group consisting of CH.sub.2 .dbd.CH--CH.sub.2 --, HO--CH.sub.2 CH.sub.2 CH.sub.2 --, and CH.sub.3 ;wherein R.sub.1 is selected from the group consisting of m-trifluoromethylphenylmethyl, 2-thienylmethyl, and p-aminosulfonylphenylethyl;wherein R.sub.2 and R.sub.3 are methyl or hydrogen;wherein R.sub.4 is hydrogen or --OH;a compound of the formula ##STR2## wherein R is (CH.sub.3).sub.2 NCH.sub.2 CH.sub.2 CH.sub.2 -- or NH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 --;or a compound of the formula ##STR3## wherein the dashed line indicates that the 2-3 bond is saturated or unsaturated and, wherein R is hydrogen or methyl.These compounds are useful for inhibiting adverse physiological symptoms associated with phospholipase A.sub.2 and for treating hyperglycemia associated diseases such as diabetes and obesity.